Suppression of multiple mouse models of refractory malignancies by reprogramming IL-18 ligand-receptor interaction



Summary

Researchers developed a novel immunotherapeutic strategy that reprograms the IL-18 pathway to combat refractory malignancies in mice. By engineering a “decoy” IL-18 binding protein (IL-18BP), they were able to effectively suppress tumor growth across several mouse models of aggressive cancers, including melanoma and leukemia. The engineered decoy, with enhanced affinity for IL-18 and resistance to inactivation, neutralizes the cytokine’s protumorigenic activity. This approach demonstrated promising anti-tumor efficacy, suggesting a potential therapeutic avenue for human cancers resistant to existing treatments by targeting and modulating the IL-18 signaling pathway.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!